Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Neuroendocrinology 1996;63:237–243

Endocrine Effects of Recombinant Interleukin 6 in Man

Späth-Schwalbe E. · Schrezenmeier H. · Bornstein S. · Burger K. · Porzsolt F. · Born J.

Author affiliations

Department of Internal Medicine, University of Ulm; Department of Internal Medicine, University of Leipzig; Sandoz Pharma Ltd., Nümberg and Department of Clinical Neuroendocrinology, University of Lübeck, Germany

Corresponding Author

Dr. E. Späth-Schwalbe, Universitätsklinik Ulm, Medizinische Klinik, Innere Medizin III, Robert-Koch-Strasse 8, D-89081 Ulm (Germany)

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


In a phase II study, 5 male patients with a good performance status, who had metastatic renal cell carcinoma, received interleukin 6 (IL-6) to evaluate a possible antitumor effect of the cytokine. This offered the opportunity to investigate endocrine effects of IL-6 in man. The patients were studied the day before (day – 1), and on days + 1 and + 21 of the IL-6 therapy (150 µg administered subcutaneously every day at 09.00 h). Blood was sampled at 09.00, 11.00, 13.00, 16.00, and 20.00 h. Compared with day-1, on days + 1 and + 21 serum levels of IL-6 were substantially elevated between 11.00 and 20.00 h. IL-6 significantly decreased serum thyrotropin (TSH) levels on day + 1 (p < 0.05). The decrease was even more pronounced on day +21 when TSH concentrations were persistently below the respective values of day +1 suggesting, in addition to the acute action of IL-6, an effect developing with repeated IL-6 administrations. Total serum T3 and T4 levels were significantly lower on day +21 than on days -1 and +1. In contrast, free T3 and free T4 values did not differ among days -1, +1 and +21. Acutely, IL-6 had no effect on serum luteinizing hormone (LH) concentrations. However, on day + 21, averaged serum LH levels (between 11.00 and 20.00 h) were significantly higher (8.4 ± 1.1 IU/l) than on days – 1 (6.5 ± 0.2 IU/l) and +1 (6.4 ± 0.4 IU/l). Average serum testosterone levels were slightly but not significantly enhanced on day + 21. IL-6 did not influence follicle-stimulating hormone, growth hormone, or prolactin levels, neither acutely nor after 3 weeks of daily administration. The data indicate a modulating effect of IL-6 on secretory activity of different endocrine axes in man.

© 1996 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Neuroimmune Interactions

Received: May 04, 1995
Accepted: October 02, 1995
Published online: April 09, 2008

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: http://www.karger.com/NEN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.